Cytokinetics (CYTK) Current Deferred Revenue (2011 - 2026)
Cytokinetics (CYTK) posted quarterly Current Deferred Revenue of $1.7 million for Q1 2026, down 96.84% year-over-year from $52.4 million in Q1 2025, and up 2.54% quarter-over-quarter from $1.6 million in Q4 2025.
Cytokinetics (CYTK) Current Deferred Revenue (2011 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported Current Deferred Revenue for 11 consecutive years, with $1.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Deferred Revenue fell 96.84% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $1.7 million (down 96.84% YoY), while the FY2025 annual figure was $1.6 million, down 96.92% from the prior year.
- Current Deferred Revenue rose to $1.7 million in Q1 2026 per CYTK's latest filing, from $1.6 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $52.4 million in Q4 2024 and bottomed at $1.3 million in Q2 2025.
- Historically, Current Deferred Revenue has averaged $18.5 million across 3 years, with a median of $1.6 million in 2025.
- Annual changes were most pronounced in 2025 — Current Deferred Revenue tumbled 96.92% — and 2026, when it sank 96.84%.
- Cytokinetics' Current Deferred Revenue stood at $52.4 million in 2024, then sank by 96.92% to $1.6 million in 2025, then rose by 2.54% to $1.7 million in 2026.
- Business Quant data shows CYTK's Current Deferred Revenue at $1.7 million in Q1 2026, $1.6 million in Q4 2025, and $1.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Cytokinetics | 10.31 Bn | 9.14 Bn | 25.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.65 Mn |
| Mar 31, 2026 | 1.65 Mn |
| Dec 31, 2025 | 1.61 Mn |
| Sep 30, 2025 | 1.61 Mn |
| Jun 30, 2025 | 1.34 Mn |
| Mar 31, 2025 | 52.37 Mn |
| Dec 31, 2024 | 52.37 Mn |
| Jun 30, 2018 | 6.25 Mn |
| Mar 31, 2018 | 3.34 Mn |
| Dec 31, 2017 | 9.57 Mn |
| Sep 30, 2017 | 9.57 Mn |
| Jun 30, 2017 | 7.94 Mn |
| Mar 31, 2017 | 10.97 Mn |
| Dec 31, 2016 | 8.06 Mn |
| Sep 30, 2016 | 10.50 Mn |
| Jun 30, 2016 | 13.56 Mn |
| Mar 31, 2016 | 15.91 Mn |
| Dec 31, 2015 | 20.86 Mn |
| Sep 30, 2015 | 110,000.00 |
| Jun 30, 2015 | 89,000.00 |